Drug Profile
Omega-3 carboxylic acids - AstraZeneca
Alternative Names: AZD 0585; D-5884; DHA/EPA - AstraZeneca; Docosahexaenoic acid/eicosapentaenoic acid - AstraZeneca; Eicosapentaenoic acid/docosahexaenoic acid - AstraZeneca; EPA/DHA - AstraZeneca; Epanova; Omefas; PurepaLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Tillotts Pharma
- Developer AstraZeneca; Cleveland Clinic; Tillotts Pharma
- Class Antihyperlipidaemics; Carboxylic acids; Docosahexaenoic acids; Eicosanoids; Hepatoprotectants; Omega 3 fatty acids; Omega-6 fatty acids
- Mechanism of Action Lipid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Hypertriglyceridaemia
- Discontinued Cardiovascular disorders; Crohn's disease; Non-alcoholic fatty liver disease
Most Recent Events
- 01 Apr 2021 Discontinued - Phase-II for Hypertriglyceridaemia in Sweden, Latvia, Slovakia (PO) due to strategic reason (AstraZeneca pipeline, May 2021)
- 01 Apr 2021 Discontinued - Phase-II for Non-alcoholic fatty liver disease (Combination therapy) in Sweden (PO) due to strategic reason (AstraZeneca pipeline, May 2021)
- 01 Apr 2021 Discontinued - Phase-II/III for Hypertriglyceridaemia (Monotherapy) in Russia, India (PO) due to strategic reason (AstraZeneca pipeline, May 2021)